Treatment Based On BRCA1 Expression Levels Does Not Increase Survival Rate of Stage II and III Non-Small Cell Lung Cancer N+ Resected Patients
New research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy (CT) treatment based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among those patients who received individualized CT treatment. However, BRCA1 expression levels could […]